Lymphangioleiomyomatosis, multifocal micronodular pneumocyte hyperplasia, and sarcoidosis : More pathological findings in the same chest CT, or a single pathological pathway? by F. Di Marco et al.
Di Marco et al. BMC Pulmonary Medicine  (2017) 17:107 
DOI 10.1186/s12890-017-0447-xCASE REPORT Open AccessLymphangioleiomyomatosis, multifocal
micronodular pneumocyte hyperplasia, and
sarcoidosis: more pathological findings in
the same chest CT, or a single pathological
pathway?
Fabiano Di Marco1*, Giuseppina Palumbo1, Silvia Terraneo1, Gianluca Imeri1, Elena Lesma2, Nicola Sverzellati3,
Angela Peron4, Lorenzo Gualandri5, Maria Paola Canevini4 and Stefano Centanni6Abstract
Background: Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome, lymphangioleiomyomatosis/tuberous
sclerosis complex (LAM-TSC), and sarcoidosis are three rare diseases. Here we present, to the best of our knowledge,
the first description of a patient with the coexistence of these three diseases.
Case presentation: A 47-year-old woman affected by LAM-TSC and primary biliary cirrosis/autoimmune hepatitis
overlap syndrome. During her follow up a high resolution chest CT scan (HRTC) confirmed the presence of both
multiple cysts and micronodular opacities consistent with multifocal micronodular pneumocytes hyperlasia
(MMPH), and revealed multiple hilar-mediastinal symmetrical lymphadenopathies suggestive of sarcoidosis.
Simultaneously, subcutaneous nodules appeared on her forearm bilaterally. Cutaneous biopsy showed
granulomatous dermatitis with sarcoid-like granulomas. A diagnosis of stage I pulmonary sarcoidosis was made. No
treatment for sarcoidosis was initiated since the patient had neither systemic involvement, nor respiratory impairment.
Conclusions: The presence of more than one rare disease should challenge the concept of a potential common
underlying mechanism, since the a priori probability of the concomitant presence of different conditions with
different pathogenic mechanisms - especially if rare diseases - is low.
We speculate that the dysregulation of the pathway involving mTOR and MAPK and their interaction might
play a role in the pathogenesis of other diseases, including sarcoidosis.
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Tuberous sclerosis complex (TSC) is a rare genetic
disorder, characterized by predominantly benign tumours
developing potentially in all organ systems. Pulmonary in-
volvement consists of Lymphangioleiomyomatosis (LAM)
and Multifocal Micronodular Pneumocyte Hyperplasia
(MMPH), which cause cystic and nodular diseases, re-
spectively. Pneumothorax and chylothorax are common* Correspondence: fabiano.dimarco@unimi.it
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LAM with new pulmonary findings.Case presentation
A 47-year-old woman, affected by TSC with a mutation
identified in the TSC1 gene [c.682C > T (p.Arg228*)], was
referred to the TSC Clinic of San Paolo Hospital (Milan,
Italy). Family history was noticeable for Addison’s disease
and brain glioblastoma (in her mother) and idiopatic pul-
monary fibrosis (in her father). Her daughter was affected
by TSC. The patient suffered from primary biliaryle is distributed under the terms of the Creative Commons Attribution 4.0
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treated with ursodeoxycholic acid (15 mg/kg/day).
She received a diagnosis of LAM by chest CT scan,
which showed bilateral lung cysts randomly distributed
thoughout the lungs. Chest CT scan revealed also the pres-
ence of sclerotic bone lesions. Pulmonary function tests
were normal, such as the 6-min walking test. Vascular
endothelial growth factor (VEGF)-D, a lymphangiogenic
growth factor proposed as a biomarker for LAM diagnosis
and severity, was 582 pg/mL (normal limits 153–642 pg/
mL). Dermatological examination showed hypomelanotic
macules, facial angiofibromas, xantelasma palpebrarum,
periungual fibromas and erythematous plaque on the left
knee. She had a renal angiomyolipoma of 4.2 cm in the left
kidney. Brain magnetic resonance (MR) showed the pres-
ence of cortical tubers. There was no ocular or heart
involvement.
One year later, the patient was adressed to our clinic. A
new high resolution chest CT scan (HRTC) was performed,
and confirmed the presence of both multiple cysts and
micronodular opacities, consistent with MMPH. Multiple
hilar-mediastinal lymphadenopathies were also identified.
Of note, hilar lymphadenopathies were symmetrically
enlarged (Fig. 1). Simultaneously, subcutaneous nodules
appeared on the patient’s forearm bilaterally (Fig. 1e),
prompting a biopsy that resulted in the hystopathologic
diagnosis of non-necrotizing granulomas, with mono- and
multinucleate epithelioid cells, some of them with asteroid
bodies surrounded by a sparse lymphocytic infiltrate,
suggestive of granulomatous dermatitis with sarcoid-like
granulomas. Diseases other than sarcoidosis were ruled out
by second line evaluations on histology samples, such as
Ziehl-Neelsen, periodic acid-Schiff (PAS), and Giemsa
staining techniques. Immunologic studies showed positive
antimitochondrial antibody and antinuclear antibody (titreFig. 1 a The mediastinal window HRCT image shows symmetrical hilar and
lung cysts (arrows) consistent with lymphangioleiomyomatosis and eith
painless, hard papules and nodules covered by eritematous skin on the1:1280, speckled pattern). IgG, IgM and IgA levels resulted
within normal range. HIV test was negative. Other causes
of granulomatous disease such as drug-induced hypersen-
sitivity, pneumoconiosis, pulmonary histiocytic disorders,
diseases associated with vascular inflammation were ruled
out through clinical history, examination and the results of
instrumental tests.
Thus, a diagnosis of sarcoidosis was considered. In
order to evaluate the extent of the disease, laboratory
tests were performed and showed normal serum angio-
tensin conversion enzyme (ACE) and serum and urinary
calcium levels. Abdominal ultrasonography showed an
enlarged liver with irregular edges and nodular heteroge-
neous echotexture, with mild steatosis and multiple
renal cysts without evidence of nephrolithiasis. Bilateral
x-ray of the hands did not show alterations in bone
structure. The ophthalmologic examination, including
funduscopic evaluation showed no signs of uveitis and
confirmed the absence of retinal hamartomas and achro-
mic patches related to TSC. EKG and echocardiography
showed no abnormalities. Pulmonary function tests, in-
cluding spirometry and lung volumes were normal; a
mild reduction in diffusing capacity for carbon mono-
xide was detected. The six-minute walk test was normal.
A diagnosis of stage I pulmonary sarcoidosis was made.
No treatment for sarcoidosis was initiated since the pa-
tient had neither systemic involvement, nor respiratory
impairment. A treatment with Sirolimus was not per-
formed due to the limited pulmonary cystic involvement
and the lack of respiratory symptoms, and a clinical
follow-up was carried on.
Discussion and conclusions
This case report represents the first description of the co-
existence of three rare disorders: autoimmune hepatitis/subcarinal enlarged lymphnodes. b-d HRCT images show scattered
er solid or subsolid micronodules (circles). e Multiple subcutaneous
left forearm
Di Marco et al. BMC Pulmonary Medicine  (2017) 17:107 Page 3 of 4primary biliary cirrhosis overlap syndrome, TSC/LAM,
and sarcoidosis. The presence of more than one rare dis-
ease should challenge the concept of a potential common
underlying mechanism.
Lymphadenopathy, both thoracic and abdominal, has
been described as another possible feature of LAM. For
instance, a recent study on 138 patients with LAM, both
sporadic and associated with TSC, found a prevalence of
9.4% for mediastinum and pulmonary hilum lymphatic
lesions [1]. However, the presence of granulomatous skin
lesions has not yet been described in LAM associated
with TSC. Thus, the results of the skin biopsy together
with the presence of bilateral hilar lymphadenopathy
lead to the diagnosis of sarcoidosis.
With respect to sarcoidosis, the importance of host
susceptibility and gene-environment interaction is widely
accepted [2]. Although sarcoidosis does not meet the
criteria for autoimmune disease, it can coexist with a wide
range of autoimmune disorders, including primary biliary
cirrhosis, which is characterized by hepatic granulomas
formation, connective tissue diseases (e.g. systemic scler-
osis and Sjogren’s syndrome), Addison’s disease, and thy-
roiditis [3]. It is noteworthy that the diagnosis of
sarcoidosis in case of granulomatous skin lesions is
made by exclusion criteria. Granulomatous lesions have
been described in case of granulomatous-lymphocytic
interstitial lung disease (GLILD) associated with com-
mon variable immunodeficiency (CVID), drug toxicity,
or infections such as tuberculosis or fungal infections.
All the aforementioned diagnoses were ruled out in our
patient. As previously stated, the association between
granulomatous lesions and autoimmune hepatitis/PBC,
such as other immune-mediated and chronic inflamma-
tory disease, has been previously described [4].
TSC is an autosomal-dominant disease caused by
heterozygous loss-of-function mutations in the TSC1
(chromosome 9q34) or TSC2 (chromosome 16p13)
tumour suppressor genes coding for hamartin and
tuberin, respectively. Tuberin and hamartin, together
with TBC1D7, form a complex that functions as a
negative regulator of mammalian target of rapamycin
(mTOR) through the inhibition of Rheb. Inactivation
of TSC1 or TSC2 results in overactivation of mTOR
leading to abnormal cell growth, proliferation, meta-
bolism, and angiogenesis. A common molecular mecha-
nism for LAM/TSC and sarcoidosis is not known.
However, a strong immunoreactivity for cathepsin-k
was demonstrated in spindle and epithelioid-shaped
cells of lung LAM and in granulomas of sarcoidosis
cases [5]. Since it is known that modulation of cathepsin-k
may occur through the mTOR pathway, it is possible to
speculate that the mTOR pathway might play a role in sar-
coidosis [6]. Several evidences demonstrated an integration
of signaling of the mTOR pathway and mitogen-activatedprotein kinases (MAPKs)-Erk activation. For instance, vas-
cular endothelial growth factor (VEGF), a lymphangiogenic
growth factor present at high levels in serum and urine of
patients with LAM, induces phosphorylation of Akt,
mTOR, S6 K, S6 and MAPK-Erk. Uncontrolled inflamma-
tion and chronic inflammatory diseases may be caused by
the persistent activation of MAPKs, which can occur in
sarcoidosis [7]. This finding suggests an explanation for the
persistent production of several inflammatory cytokines,
such as TNF-α and IL-12, in sarcoidosis. Interestingly,
Linke et al. found that activation of mTORC1 due to TSC2
deficiency causes granulomatous disease, including sar-
coidosis, in both mice and humans. mTORC1 inhibition
resolves granulomas in TSC2-deficient mice, suggesting
that treatment with mTOR inhibitors, used to stop the
progression of benign tumors and LAM in TSC, might im-
prove the signs of sarcoidosis as well [8]. However, the rea-
son why not all patients with TSC develop sarcoidosis is
still unknown.
Although at present it is not possible to demonstrate a
common mechanism underlying LAM/TSC, sarcoidosis,
primary biliary cirrhosis and autoimmune hepatitis, and
their coexistence could well occur by chance, we might
speculate that the dysregulation of the pathway involving
mTOR and MAPK and their interaction may play a role
in the alteration of the diseases. Further reports are
needed to demonstrate our hypothesis.
Abbreviations
ACE: Serum angiotensin conversion enzyme; AMA: Antimitochondrial
antibody; HRTC: High resolution chest CT scan;
LAM: Lymphangioleiomyomatosis; MAPK: Mitogen-activated protein kinases;
MMPH: Multifocal micronodular pneumocyte hyperplasia; MR: Magnetic
resonance; MTOR: Mammalian target of rapamycin; TSC: Tuberous sclerosis
complex; VEGF: Vascular endothelial growth factor
Acknowledgements
Not applicable.
Funding
This work was not funded.
Availability of data and materials
Not applicable.
Authors’ contributions
FDM, GP, ST, GI had full access to all of the patient’s clinical data and takes
responsibility for the integrity of the data. EL, NS, MPC, SC, AP contributed
substantially to the data interpretation, and the writing of the manuscript. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient for publication of
this Case report and all accompanying images.
Competing interests
FDM is currently an Associate Editor of this journal; other authors declare
that they have no competing interests.
Di Marco et al. BMC Pulmonary Medicine  (2017) 17:107 Page 4 of 4Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Respiratory Unit, Ospedale San Paolo, Department of Health Sciences,
Università degli Studi di Milano, Via A. di Rudinì, 8, 20142 Milan, Italy.
2Laboratories of Pharmacology, Università degli Studi di Milano, Milan, Italy.
3Radiology, Department of Medicine and Surgery, University of Parma,
Parma, Italy. 4Epilepsy Center, Ospedale San Paolo, Department of Health
Sciences, Università degli Studi di Milano ASST Santi Paolo e Carlo, Milan,
Italy. 5Dermatologic Clinic, Ospedale San Paolo, ASST Santi Paolo e Carlo,
Milan, Italy. 6Respiratory Unit, Ospedale San Paolo, Department of Health
Sciences, Università degli Studi di Milano, Milan, Italy.
Received: 13 February 2017 Accepted: 18 July 2017
References
1. Tobino K, Johkoh T, Fujimoto K, et al. Computed tomographic features of
lymphangioleiomyomatosis: evaluation in 138 patients. Eur J Radiol. 2015;84:
534–41. doi:10.1016/j.ejrad.2014.12.008.
2. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–
34. doi:10.1056/NEJM199704243361706.
3. Sharma OP. Sarcoidosis and other autoimmune disorders. Curr Opin Pulm
Med. 2002;8:452–6.
4. Rajoriya N, Wotton CJ, Yeates DGR, et al. Immune-mediated and chronic
inflammatory disease in people with sarcoidosis: disease associations in
a large UK database. Postgrad Med J. 2009;85:233–7. doi:10.1136/pgmj.
2008.067769.
5. Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary
lymphangioleiomyomatosis. Mod Pathol an Off J United States Can Acad
Pathol Inc. 2009;22:161–6. doi:10.1038/modpathol.2008.189.
6. Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the
majority of malignant melanomas. J Invest Dermatol. 2008;128:980–7. doi:10.
1038/sj.jid.5701074.
7. Rastogi R, Du W, Ju D, et al. Dysregulation of p38 and MKP-1 in response to
NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit
Care Med. 2011;183:500–10. doi:10.1164/rccm.201005-0792OC.
8. Linke M, Pham HTT, Katholnig K, et al. Chronic signaling via the metabolic
checkpoint kinase mTORC1 induces macrophage granuloma formation and
marks sarcoidosis progression. Nat Immunol Published Online First: January.
2017; doi:10.1038/ni.3655.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
